Brought to you by 
Epigen Biosciences licenses LPA1 antagonist to Novo Nordisk
03 Aug 2018
Executive Summary
Novo Nordisk AS licensed rights to Epigen Biosciences Inc.’s preclinical LPA1 antagonist EPGN696, which it will develop as a treatment for diabetic and chronic kidney diseases and other conditions related to metabolic syndrome.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epigen Biosciences licenses LPA1 antagonist to Novo Nordisk
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice